Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations

We analyzed the relationship between itraconazole (ITZ) and hydroxy-itraconazole (OH-ITZ) levels in 1,223 human samples. Overall, there was a statistically significant correlation between ITZ and OH-ITZ levels (Pearson’s r, 0.7838), and OH-ITZ levels were generally higher than ITZ levels (median OH-ITZ:ITZ ratio, 1.73; range, 0.13 to 8.96). ABSTRACT We analyzed the relationship between itraconazole (ITZ) and hydroxy-itraconazole (OH-ITZ) levels in 1,223 human samples. Overall, there was a statistically significant correlation between ITZ and OH-ITZ levels (Pearson’s r, 0.7838), and OH-ITZ levels were generally higher than ITZ levels (median OH-ITZ:ITZ ratio, 1.73; range, 0.13 to 8.96). However, marked variability was observed throughout the range of ITZ concentrations. Thus, it is difficult to predict OH-ITZ concentrations based solely on ITZ levels.

[1]  M. Assi,et al.  Endemic fungal infections in solid organ transplant recipients—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice , 2019, Clinical transplantation.

[2]  N. Wiederhold,et al.  Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections , 2017, Current Fungal Infection Reports.

[3]  D. Denning,et al.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  R. Gorton,et al.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. , 2014, The Journal of antimicrobial chemotherapy.

[5]  T. Patterson,et al.  A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid , 2013, Antimicrobial Agents and Chemotherapy.

[6]  D. Denning,et al.  Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[8]  M. Threlkeld,et al.  Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Baddley,et al.  Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  W. L. Nelson,et al.  ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION , 2004, Drug Metabolism and Disposition.

[11]  C. Manire,et al.  STEADY-STATE PLASMA CONCENTRATIONS OF ITRACONAZOLE AFTER ORAL ADMINISTRATION IN KEMP'S RIDLEY SEA TURTLES, LEPIDOCHELYS KEMPI , 2009, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

[12]  F. Odds,et al.  Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. , 2000, The Journal of antimicrobial chemotherapy.

[13]  M. Nucci,et al.  A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  C. Leutner,et al.  Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole , 1999, Mycoses.

[15]  H. Sugimoto,et al.  Plasma concentration of itraconazole and its antifungal prophylactic efficacy in patients with neutropenia after chemotherapy for acute leukemia , 1999, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[16]  J. Graybill,et al.  Therapeutic drug monitoring of systemic antifungal therapy. , 1997, The Journal of antimicrobial chemotherapy.

[17]  B. Gazzard,et al.  Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. , 1997, Journal of clinical pathology.

[18]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D. Denning,et al.  Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards , 1994, Antimicrobial Agents and Chemotherapy.

[20]  D. Stevens,et al.  Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations , 1993, Antimicrobial Agents and Chemotherapy.

[21]  R. M. Tucker,et al.  Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. , 1990, Journal of the American Academy of Dermatology.

[22]  G. Verhoef,et al.  Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels , 1989, Mycoses.

[23]  R. Woestenborghs,et al.  The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.

[24]  R. M. Tucker,et al.  Itraconazole therapy for cryptococcal meningitis and cryptococcosis. , 1989, Archives of internal medicine.

[25]  R. M. Tucker,et al.  Treatment of invasive aspergillosis with itraconazole. , 1989, The American journal of medicine.

[26]  D. Warnock,et al.  Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. , 1988, The Journal of antimicrobial chemotherapy.

[27]  G. Tricot,et al.  Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. , 1987, Reviews of infectious diseases.

[28]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.